Qiao Qun, Wang Xiancheng, Sun Jiaming, Zhao Ru, Liu Zhifei, Wang Yang, Sun Baodong, Yan Yinjun, Qi Keming
Department of Plastic and Cosmetic Surgery, Peking Union Medical College Hospital, Beijing, 100730, China.
Aesthetic Plast Surg. 2005 May-Jun;29(3):156-61; discussion 162. doi: 10.1007/s00266-004-0099-0.
Polyacrylamide hydrogel, a new biomaterial, has been used for injected breast augmentation in China since 1997. A series of 30 patients with various complications after injected polyacrylamide hydrogel visited the author's department. Most of these patients had undergone injection of both breasts. The average age of the patients was 27.6 years, and the time of consultation for the complications was from 3 to 36 months postopertively. Nearly all the patients had breast lumps and other common complications including breast pain, disfigurement, and infection. Ultrasound examination showed diffuse, irregular, anechoic zones of mammary tissue. Pathologic results indicated inflammatory cell infiltration and fibrous capsular formation. An open suction technique and partial mastectomies via periareolar incisions were performed for the all patients. Most of their symptoms were relieved after removal of the polyacrylamide hydrogel. Only one patient had undergone immediate breast reconstruction with implants, whereas five patients had received breast implants secondarily via an axillary incision. The authors conclude that polyacrylamide hydrogel should be prohibited for injected breast augmentation before more scientific data are available about the long effect of the gel in breast tissue.
聚丙烯酰胺水凝胶作为一种新型生物材料，自1997年起在中国被用于注射隆胸。作者所在科室接待了30例注射聚丙烯酰胺水凝胶后出现各种并发症的患者。这些患者大多双侧乳房都接受了注射。患者的平均年龄为27.6岁，出现并发症后前来咨询的时间为术后3至36个月。几乎所有患者都有乳房肿块以及其他常见并发症，包括乳房疼痛、外形受损和感染。超声检查显示乳腺组织有弥漫性、不规则的无回声区。病理结果表明有炎症细胞浸润和纤维包膜形成。对所有患者均采用了开放式抽吸技术并通过乳晕周围切口进行了部分乳房切除术。去除聚丙烯酰胺水凝胶后，大多数患者的症状得到缓解。只有1例患者立即进行了乳房假体再造，而5例患者随后通过腋窝切口接受了乳房假体植入。作者得出结论，在获得更多关于该凝胶在乳腺组织中长期影响的科学数据之前，应禁止使用聚丙烯酰胺水凝胶进行注射隆胸。
